Form 4: Madrigal CCO's Equity Grant & Tax Sale

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, received new equity grants and sold shares to cover tax obligations.

Summary

• Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (MDGL), was granted 3,989 restricted stock units (RSUs) on March 4, 2026.
• These RSUs will vest in four equal annual installments of 25% on March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, contingent on continued service.
• Huntsman also received a grant of stock options for 4,986 shares on March 4, 2026, with an exercise price of $434.8 per share.
• The stock options vest 25% on March 4, 2027, and then 6.25% quarterly thereafter, expiring on March 4, 2036, also contingent on continued service.
• On March 6, 2026, 419 shares of common stock were sold at a price of $431.94 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Huntsman directly beneficially owns 12,692 shares of common stock and 4,986 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While a sale occurred, it was for tax purposes, and the primary action was the grant of new equity, which aligns executive incentives with long-term company performance.

Positives

• The grant of restricted stock units and stock options aligns the Chief Commercial Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The equity grants are a standard component of executive compensation packages, indicating ongoing commitment to key management personnel.

Negatives

• A portion of common stock (419 shares) was sold, reducing direct beneficial ownership, although this was an automatic sale to cover tax withholding obligations and not a discretionary sale.

Risks

• The vesting of both restricted stock units and stock options is contingent upon the reporting person's continued service with the Issuer on each vesting date, posing a risk to the executive if employment ceases.
• The value of the equity grants is subject to the future performance of Madrigal Pharmaceuticals' stock price.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the vesting schedules of the granted equity.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to a Chief Commercial Officer is a standard practice in the biotechnology and pharmaceutical industry. Such equity-based compensation is crucial for attracting, retaining, and motivating key executives, aligning their long-term incentives with shareholder value creation. The sale of shares to cover tax withholding is also a routine and expected event associated with the vesting of equity awards.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Commercial Officer's long-term interests with shareholder value creation, potentially leading to improved performance.
• Employees (specifically the CCO): The grants represent a significant component of compensation, incentivizing retention and performance.

Next Steps

• The restricted stock units will vest in 25% increments annually on March 4, 2027, 2028, 2029, and 2030.
• The stock options will vest 25% on March 4, 2027, and then 6.25% quarterly thereafter until fully vested.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including equity grants and a tax-related share sale. Such transactions are standard and generally do not provide a strong signal for a 'buy' or 'sell' recommendation. The grants align management incentives, which is positive, but the overall impact on the company's fundamental valuation or immediate share price is neutral, warranting a 'hold' recommendation.

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Chief Commercial Officer, Equity Grant, Tax Withholding